Wedbush analyst Andreas Argyrides reiterated a Buy rating on ARS Pharmaceuticals (SPRY – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $2.92.
According to TipRanks, Argyrides is an analyst with an average return of -1.7% and a 34.04% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, MoonLake Immunotherapeutics, and Ascendis Pharma.
ARS Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
SPRY market cap is currently $279.1M and has a P/E ratio of -1.20.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SPRY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ARS Pharmaceuticals (SPRY) Company Description:
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Read More on SPRY:
- ARS Pharma (NASDAQ:SPRY) Plummets on FDA Snub for Epinephrine Nasal Spray
- ARS Pharmaceuticals issued CRL by FDA for neffy NDA, plans to appeal
- ARS downgraded to Market Perform from Outperform at William Blair
- FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
- ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
